Area of research
Oncology · Cancer Research
Research interest
Research interests include Cancer Cells and Metastasis, Cancer, Hypoxia, and Metabolism, Pancreatic and Hepatic Oncology Research, and Breast Cancer Treatment Studies.
Bioflavonoid luteolin prevents <scp>sFlt</scp> ‐1 release via <scp>HIF</scp> ‐1α inhibition in cultured human placenta
ER stress sensor, glucose regulatory protein 78 (GRP78) regulates redox status in pancreatic cancer thereby maintaining “stemness”
O-GlcNAc modification of Sox2 regulates self-renewal in pancreatic cancer by promoting its stability
New Roles for Glycogen in Tumor Progression
Metastasis and chemoresistance in CD133 expressing pancreatic cancer cells are dependent on their lipid raft integrity
<scp>GRP</scp>78‐mediated antioxidant response and <scp>ABC</scp> transporter activity confers chemoresistance to pancreatic cancer cells
Inactivation of Cancer-Associated-Fibroblasts Disrupts Oncogenic Signaling in Pancreatic Cancer Cells and Promotes Its Regression
NFκB-Mediated Invasiveness in CD133+ Pancreatic TICs Is Regulated by Autocrine and Paracrine Activation of IL1 Signaling
Inhibition of hypoxic response decreases stemness and reduces tumorigenic signaling due to impaired assembly of HIF1 transcription complex in pancreatic cancer
Inhibition of Sp1 prevents ER homeostasis and causes cell death by lysosomal membrane permeabilization in pancreatic cancer
Downregulation of Sp1 by Minnelide leads to decrease in HSP70 and decrease in tumor burden of gastric cancer
Microenvironment in determining chemo-resistance in pancreatic cancer: Neighborhood matters
Inhibition of NF-kappa B pathway leads to deregulation of epithelial–mesenchymal transition and neural invasion in pancreatic cancer
Microenvironment mediated alterations to metabolic pathways confer increased chemo-resistance in CD133+ tumor initiating cells